I agree with you generally, but why is it a special case? As you said,tThe problem isn't the cost to deliver a drug. There are over 100k "potentially useful" ne

I agree with you generally, but why is it a special case? As you said,tThe problem isn't the cost to deliver a drug. There are over 100k "potentially useful" new chemicals synthesized by university labs every year. One or two are brought to market. The cost is in the red tape, and doing the clinical trials to satisfy regulations. I agree, we'd have to get rid of that. But treating it as a special case ensures that we'll just put off the subject indefinitely. IP corrupts everything it touches. Get rid of it, and we'll eliminate the problem at the source.